Insider selling
Traded May 7, 2025 · filed 3 days laterNot reported under a pre-arranged trading plan
A major shareholder of Os Therapies sold $164K of Os Therapies shares. The filing does not indicate a pre-arranged trading plan.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
OSTX · NYSE · Pharmaceutical Preparations
Os Therapies (OSTX) · oqro.io/stocks/OSTX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Os Therapies is on record in SEC filings since 2006.
Since 2025, Os Therapies insiders reported 0 open-market purchases and 5 sales on Forms 4 and 5.
No open-market sale by an insider of Os Therapies (OSTX) was filed with the SEC in the last 90 days.
No trade in Os Therapies (OSTX) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$0.803−0.0174 (−2.12%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−50.4% (−$0.817) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $1.62 on Nov 20, 2025 to $0.803 on Nov 20, 2026 (−50.4%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Rockville, Md.
Last 12 months
−50.4%
Market value
$34.4M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 2.76M shares sold short (6.5% of shares outstanding), −2.1% vs the previous count, 7.7 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Insider selling
Traded May 7, 2025 · filed 3 days laterNot reported under a pre-arranged trading plan
A major shareholder of Os Therapies sold $164K of Os Therapies shares. The filing does not indicate a pre-arranged trading plan.
Traded Apr 9 – Apr 10, 2025 · largest single transaction ~$68KNot reported under a pre-arranged trading plan
Apr 9, 2025~$68K · 50K sh @ $1.35
DetailsOfficial recordApr 10, 2025~$14K · 10K sh @ $1.39
DetailsOfficial recordInsider selling
Traded Feb 14, 2025 · filed 5 days laterNot reported under a pre-arranged trading plan
A major shareholder of Os Therapies sold $284K of Os Therapies shares. The filing does not indicate a pre-arranged trading plan.
Insider selling
Traded Jan 15, 2025 · filed 3 days laterNot reported under a pre-arranged trading plan
A major shareholder of Os Therapies sold $113K of Os Therapies shares. The filing does not indicate a pre-arranged trading plan.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Os Therapies reported 0 open-market purchases and 5 sales since 2025; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2025 | — | $642K5×5 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Said its annual or quarterly report would be late
“S tate below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. OS Therapies Incorporated (the "Company") has determined that it will not be able to file its Quarterly Report on Form 10-Q for its quarter ended March 31, 2026 (the "Form 10-Q") by May 15, 2026, the original due date for such filing”
NT 10-Q on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 6,000 words.
We are a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. Our mission is to address the significant need for new treatments in cancers of the bone in children and young adults. Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to its location, changing genotypes and high metastases rates. We are currently seeking to answer the call for new treatments that will prevent metastasis and the recurrence of metastases with our lead core product candidate OST-HER2 (also known as OST31-164), a cancer immunotherapy product candidate that produces a cellular immune response against the cancer antigen HER2.
And 7 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 31, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Revenue
—
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $432K, at Sep 30, 2026
Net income, last 12 months
−$43.8M
Operating loss: profit did not cover interest (last 3 quarters)
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 19, 2025.
Revenue and earnings history, 3 fiscal yearsEarnings dates and the stock's moves
Against the S&P 500 over the year
Since Nov 18, 2025, OSTX is down 53.6% and the index fund is up 4.5%: 58 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much OSTX moves
Beta 1.6 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).
Off-exchange trading: 60.6% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (7.0% on ATS, 53.6% with other brokers), above its 26-week average of 56.5%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: MS POOL (ATS-4) (22.6%), INTELLIGENT CROSS LLC (14.7%), IBKR ATS (7.3%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Latest annual report filed Mar 31, 2026, compared with the one filed Mar 31, 2025. Read the filing
The information contained in Note 6 to our consolidated financial statements included in this Form 10-K is incorporated herein by reference.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Mar 31, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.